NCT06145139 (KIDNEY-PAGER) is a clinical trial in Renal Cancer, sponsored by University of Aarhus.

Who is sponsoring NCT06145139?

NCT06145139 is sponsored by University of Aarhus.

What condition does NCT06145139 study?

NCT06145139 studies Renal Cancer.

Is NCT06145139 still recruiting?

NCT06145139 is currently enrolling by invitation. Last updated 22 November 2023.

Last reviewed 2023-11-22 · How we verify

NCT06145139: KIDNEY-PAGER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial

ENROLLING BY INVITATION Last updated 22 November 2023

What this trial tests

trial in Renal Cancer in 500 participants. Enrolling by invitation.

Timeline

1 June 2023

Primary endpoint
1 June 2028

1 June 2033

Quick facts

Lead sponsor	University of Aarhus
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 June 2023
Primary completion	1 June 2028
Estimated completion	1 June 2033
Sites	1 location across Denmark

Conditions studied

Renal Cancer — all drugs for Renal Cancer →

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Renal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as a marker of subclinical residual disease and risk of recurrence.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer - an observational trial. Study protocol.
Iisager L, Ahrenfeldt J, Keller AK, Nielsen TK, et al · · 2024 · cited 6× · PMID 38391290 · DOI 10.2340/1651-226x.2024.25581
Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers.
Kato T, Yajima S, Nakamura Y, Kobayashi S, et al · · 2025 · cited 2× · PMID 40955810 · DOI 10.1111/iju.70215
Using ctDNA to Inform Adjuvant Therapy for Urologic Malignancies.
Goradia R, Goodstein T, Sundi D, Sood A, et al · · 2026 · PMID 41976347 · DOI 10.3390/cancers18071121

Verify or expand the search:

Other recruiting trials for Renal Cancer

Currently open trials in the same condition.

NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07037589 — Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
NCT07141225 — Application of the "Off-Clamp And Sutureless" Technique in Robot-Assisted Partial Nephrectomy · NA · recruiting
NCT07303725 — Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06145139 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 22 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing